We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET-CT Theranostic Agent Could Help Detect Pancreatic Tumors

By MedImaging International staff writers
Posted on 30 Jun 2017
Print article
Image: Metastatic pancreatic adenocarcinoma on axial fused PET/CT image with Zr-89 HuMab-5B1, which correlates with increased liver metastasis on diagnostic CT (Photo courtesy of Christian Lohrmann / MSKCC).
Image: Metastatic pancreatic adenocarcinoma on axial fused PET/CT image with Zr-89 HuMab-5B1, which correlates with increased liver metastasis on diagnostic CT (Photo courtesy of Christian Lohrmann / MSKCC).
A monoclonal antibody-based improved positron emission tomography/computed tomography (PET/CT) agent could prove useful for diagnosing and treating patients with pancreatic cancer, according to a new study.

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA) conducted a study to investigate the human monoclonal antibody HuMab-5B1, which targets the cancer antigen CA 19-9. The antigen is expressed on tumors of the pancreas and other malignancies, including small cell lung cancer (SCLC) and tumors of the gastrointestinal (GI) system. For the study, nine patients with metastatic malignancies that were positive for CA 19-9 received four whole-body PET/CT scans, both with and without radiolabeling with zirconium-89. CT scans were performed before the baseline PET/CT to verify the results of the radiotracer.

The first PET/CT scan was performed on the first day of injection with the imaging agent, and again on day two and around days four and seven. The results showed significant tracer uptake in local tumor recurrences, as well as in metastases, with the highest uptake seen on day seven in the lymph nodes. PET/CT scans of HuMab-5B1 radiolabeled with zirconium-89 led to the detection of very small tumors in the peritoneum and mesenteric lymph nodes not seen by CT alone. The study was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held during June 2017 in Denver (CO, USA).

“This new agent is intensely accumulated in pancreatic cancer and finds very small metastases with PET/CT imaging. What's more, the antibody's high uptake suggests it could be used either by itself or coupled with another molecular compound to treat,” said lead author and study presenter Christian Lohrmann, MD. “There are promising data that HuMab-5B1 could become a theranostic drug used in both targeted imaging and therapy, which could eventually improve the prognosis for pancreatic cancer patients.”

Theranostics use specific biological pathways to acquire diagnostic images and deliver a therapeutic dose of radiation. Once a specific diagnostic test shows a particular molecular target on a tumor, the therapy agent can be specifically targeted to that receptor, providing a more targeted and efficient form of pharmacotherapy.

Related Links:
Memorial Sloan-Kettering Cancer Center

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Brachytherapy Planning System
Oncentra Brachy
Ultrasound System
P25 Elite
Digital Radiography Acquisition Software
VXvue with PureImpact

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.